Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the effect of application of Dinitrochlorobenzene (DNCB) on the number, morphology, and antigen expression of epidermal Langerhans cells in AIDS and AIDS related complex (ARC) patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dinitrochlorobenzene

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients must have the following:

* Stage III or IV HIV infection.
* Provide informed consent.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

* Kaposi's sarcoma lesions in the proposed treatment sites.
* Liable to require radiation or chemotherapy during the course of the study.
* Not likely to survive the length of the study.
* Obvious ultra-violet-irradiated skin damage in the treatment areas and anyone with recent UV exposure or likely to have such exposure (e.g.:
* holiday tans obtained in Hawaii, members of UV box tanning salons, etc.) Allergy to lidocaine.

Concurrent Medication:

Excluded:

* Other Immunomodulators.

Concurrent Treatment:

Excluded:

* Radiation.

Patients with the following are excluded:

* Kaposi's sarcoma lesions in the proposed treatment sites.
* Liable to require radiation or chemotherapy during the course of the study.
* Not likely to survive the length of the study.
* Obvious ultra-violet-irradiated skin damage in the treatment areas.
* Allergy to lidocaine.

Prior Medication:

Excluded:

* Prior DNCB therapy.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

San Francisco AIDS Clinic / San Francisco Gen Hosp

San Francisco, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Stricker RB, Elswood BF. Dendritic cells and dinitrochlorobenzene (DNCB): a new treatment approach to AIDS. Immunol Lett. 1991 Aug;29(3):191-6. doi: 10.1016/0165-2478(91)90169-b.

Reference Type BACKGROUND

PMID: 1769706 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

047A

Identifier Type: -

Identifier Source: org_study_id